Ascelia Pharma AB (publ) (STO:ACE)

Sweden flag Sweden · Delayed Price · Currency is SEK
3.215
-0.005 (-0.16%)
Dec 30, 2025, 5:29 PM CET
6.11%
Market Cap407.71M
Revenue (ttm)n/a
Net Income (ttm)-88.72M
Shares Out126.82M
EPS (ttm)-0.84
PE Ration/a
Forward PE80.38
Dividendn/a
Ex-Dividend Daten/a
Volume563,903
Average Volume1,010,983
Open3.255
Previous Close3.220
Day's Range3.150 - 3.285
52-Week Range2.305 - 5.230
Beta1.06
RSI63.22
Earnings DateFeb 5, 2026

About Ascelia Pharma AB

Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headq... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 11
Stock Exchange Nasdaq Stockholm
Ticker Symbol ACE
Full Company Profile

Financial Performance

Financial Statements

News

Ascelia Pharma AB (FRA:7ZA) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial ...

Ascelia Pharma AB (FRA:7ZA) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial Strength

2 months ago - GuruFocus

Q3 2025 Ascelia Pharma AB Earnings Call Transcript

Q3 2025 Ascelia Pharma AB Earnings Call Transcript

2 months ago - GuruFocus

Ascelia Pharma AB (FRA:7ZA) Q2 2025 Earnings Call Highlights: Strategic Moves and Market ...

Ascelia Pharma AB (FRA:7ZA) Q2 2025 Earnings Call Highlights: Strategic Moves and Market Potential for Orviglance

4 months ago - GuruFocus

Q2 2025 Ascelia Pharma AB Earnings Call Transcript

Q2 2025 Ascelia Pharma AB Earnings Call Transcript

4 months ago - GuruFocus